Protecting Skin Health As You Age: What the Evidence Actually Shows

Skin aging is driven by two largely separate processes — intrinsic aging (genetically programmed, time-dependent decline) and photoaging (cumulative UV damage) — and the distinction matters because only one of them is substantially preventable. This article reviews what controlled evidence actually supports for slowing visible skin aging: sun protection, topical retinoids, and antioxidants such as vitamin C. It also looks honestly at where regenerative-medicine-adjacent products — stem cell-derived exosome and "secretome" skincare — stand today, and why most of those claims currently outrun the data.

Why Skin Ages: Two Processes, Not One

The National Library of Medicine's MedlinePlus describes sun exposure as "a major cause of skin aging," and also names smoking as a contributor, noting that wrinkling tends to increase with the number of cigarettes and years smoked. Separately, skin ages intrinsically with time regardless of sun exposure — it thins, loses underlying fat, and becomes less plump and slower to heal. Because photoaging is cumulative and largely avoidable, it is also the piece of the picture dermatology has the most leverage over.

What the Evidence Actually Supports

Sun protection has the strongest and most consistent evidence base of any skin-aging intervention. The American Academy of Dermatology recommends a broad-spectrum sunscreen (protecting against both UVA and UVB) of SPF 30 or higher, reapplied and chosen with water resistance (rated for either 40 or 80 minutes) in mind for activity in water or sweat. Because UVA wavelengths penetrate deeply and drive much of the collagen-damaging photoaging process, broad-spectrum coverage — not SPF alone — is the key label detail.

Retinoids are evidence-supported, but strength of evidence depends heavily on formulation. Prescription tretinoin (Renova) is FDA-approved as an adjunct therapy for mitigating fine wrinkles, mottled hyperpigmentation, and tactile roughness. In trials supporting that approval, moderate improvement in fine wrinkling occurred in 24% of tretinoin-treated patients versus 8% on vehicle over 24 weeks — real but modest, and the FDA label states tretinoin does not eliminate wrinkles or reverse photoaging. Over-the-counter retinol is a different story: a 2021 systematic review in The Journal of Clinical and Aesthetic Dermatology examined nine randomized, vehicle-controlled OTC retinol trials; four showed no significant benefit over vehicle, and the remaining five suggested only a possible mild effect on fine lines, with notable methodological limitations. The reviewer concluded there is "very little, if any, trustworthy evidence" for OTC retinol's anti-aging claims as currently studied — a more cautious verdict than retinoid marketing generally implies.

Topical antioxidants, particularly vitamin C, have biologically plausible, partially supported evidence. A review in The Journal of Clinical and Aesthetic Dermatology cites small placebo-controlled trials (10 to 20 subjects) showing protective effects against photoaging, while noting "clinical studies on the efficacy of topical formulations of vitamin C remain limited." The direction is favorable; the sample sizes are not yet large.

Where Regenerative Approaches Stand Today

Stem cell-derived exosome and "secretome" serums have become common in aesthetic skincare marketing. Exosomes are real, well-characterized extracellular vesicles involved in cell-to-cell signaling, and that underlying biology is genuinely studied. But clinical evidence for topical cosmetic exosome products in humans remains preclinical or early-phase: supporting data largely comes from cultured-cell and animal-skin studies, not large controlled human trials, and no exosome product currently holds FDA approval for any dermatologic or aesthetic use. The regulatory context matters here: most topical cosmetic products, including these, are marketed as cosmetics rather than drugs, so they are not required to demonstrate efficacy or undergo FDA drug review before sale. The FDA has separately warned that unapproved, injectable cell-derived products have been linked to serious adverse events — including a 2019 safety notification after reported infections in Nebraska — and continues issuing warning letters to manufacturers of unapproved cell-based products.

What's Still Unproven or Overhyped

Claims that topical exosome or "secretome" serums can regenerate skin, reverse aging, or substitute for sun protection and retinoids are not supported by current human trial evidence. The same caution applies to marketing language implying these products are medically equivalent to prescription treatments; cosmetic status specifically means they have not cleared that bar.

Bottom Line

The best-supported tools for visible skin aging remain unglamorous: daily broad-spectrum SPF 30+ sunscreen, and, for some people, prescription-strength retinoids used consistently over months. Topical vitamin C has promising but still limited human evidence. Regenerative-medicine-derived skincare — exosomes and secretomes — rests on real cell biology but has not yet produced the large, controlled human trials needed to support the claims often made for it, and buyers should understand that cosmetic marketing status means no efficacy review was required. Evidence-based skin aging prevention today is less about novel ingredients and more about consistency with the few interventions that have actually been tested.